Standard
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy. / Eriksen, M.; Yde, C. W.; Ahlborn, L. B.; Qvortrup, C.; Lassen, U.; Højgaard, M.; Spanggaard, I.; Rohrberg, K. S.
I:
European Journal of Cancer, Bind 174, Nr. S1, 2022, s. S118.
Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › fagfællebedømt
Harvard
Eriksen, M, Yde, CW, Ahlborn, LB
, Qvortrup, C, Lassen, U, Højgaard, M, Spanggaard, I & Rohrberg, KS 2022, '
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy',
European Journal of Cancer, bind 174, nr. S1, s. S118.
https://doi.org/10.1016/S0959-8049(22)01115-7APA
Eriksen, M., Yde, C. W., Ahlborn, L. B.
, Qvortrup, C., Lassen, U., Højgaard, M., Spanggaard, I., & Rohrberg, K. S. (2022).
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy.
European Journal of Cancer,
174(S1), S118.
https://doi.org/10.1016/S0959-8049(22)01115-7Vancouver
Eriksen M, Yde CW, Ahlborn LB
, Qvortrup C, Lassen U, Højgaard M o.a.
TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy.
European Journal of Cancer. 2022;174(S1):S118.
https://doi.org/10.1016/S0959-8049(22)01115-7Author
Eriksen, M. ; Yde, C. W. ; Ahlborn, L. B. ; Qvortrup, C. ; Lassen, U. ; Højgaard, M. ; Spanggaard, I. ; Rohrberg, K. S. / TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy. I: European Journal of Cancer. 2022 ; Bind 174, Nr. S1. s. S118.
Bibtex
@article{0871bb31f8084fe688223712949cf743,
title = "TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy",
author = "M. Eriksen and Yde, {C. W.} and Ahlborn, {L. B.} and C. Qvortrup and U. Lassen and M. H{\o}jgaard and I. Spanggaard and Rohrberg, {K. S.}",
year = "2022",
doi = "10.1016/S0959-8049(22)01115-7",
language = "English",
volume = "174",
pages = "S118",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",
number = "S1",
}
RIS
TY - ABST
T1 - TP53 mutations are frequently concurrent in patients with BRAF V600E mutated solid tumors and is associated with shorter duration of response to BRAF targeted therapy
AU - Eriksen, M.
AU - Yde, C. W.
AU - Ahlborn, L. B.
AU - Qvortrup, C.
AU - Lassen, U.
AU - Højgaard, M.
AU - Spanggaard, I.
AU - Rohrberg, K. S.
PY - 2022
Y1 - 2022
U2 - 10.1016/S0959-8049(22)01115-7
DO - 10.1016/S0959-8049(22)01115-7
M3 - Conference abstract in journal
AN - SCOPUS:85144025529
VL - 174
SP - S118
JO - European Journal of Cancer, Supplement
JF - European Journal of Cancer, Supplement
SN - 0959-8049
IS - S1
ER -
